ENGN Financials: enGene Therapeutics Inc AI Analysis



Financials

ENGN Financial

enGene Therapeutics Inc

$1.72

-80.56%

$-7.13

At close: May 07, 16:00:00 GMT-4

$1.72

0.02%

$0

Post-market: May 07, 19:36:55 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$8.85

Open

$2.14

Day's Range

$1.7 - $2.24

52 week range

$1.72 - $12.25

Volume

23.4M

Avg.Volume

401.2K

Dividend yield

EPS (TTM)

-2.25

Market Cap

$115.2M

What is ENGN?

enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).

Features

Markets

News

Income

Balance sheet

Cash flow

Annual

Quarterly

ENGN Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	01/31/2026	10/31/2025	07/31/2025	04/30/2025	01/31/2025
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	30	8	7	7	6	6
Research & Development	96	22	31	22	20	19
Operating Expenses	127	31	39	29	27	26
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-122	-29	-38	-28	-25	-24
Income Tax Expense	0	0	0	0	0	0
Net Income	-122	-29	-37	-28	-25	-24
Net Income Growth	77%	21%	147%	100%	79%	140%
Shares Outstanding (Diluted)	67.26	67.26	51.38	51.09	51.01	50.97
Shares Change (YoY)	32%	32%	16%	16%	28.99%	120%
EPS (Diluted)	-1.82	-0.44	-0.73	-0.56	-0.5	-0.48
EPS Growth	35%	-8%	113.99%	77%	33%	5%
Free Cash Flow	-103	-29	-25	-26	-22	-25
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-127	-31	-39	-29	-27	-26
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-127	-31	-39	-29	-27	-26
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are enGene Therapeutics Inc's key financial statements?



According to the latest financial statement (Form-10K), enGene Therapeutics Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for ENGN?



enGene Therapeutics Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is enGene Therapeutics Inc's revenue broken down by segment or geography?



enGene Therapeutics Inc largest revenue segment is Creative Subscriptions, at a revenue of 1,409,727,000 in the most earnings release.For geography, Europe is the primary market for enGene Therapeutics Inc, at a revenue of 506,861,000.

Is enGene Therapeutics Inc profitable?



no, according to the latest financial statements, enGene Therapeutics Inc has a net loss of $0

Does enGene Therapeutics Inc have any liabilities?



no, enGene Therapeutics Inc has liability of 0

How many outstanding shares for enGene Therapeutics Inc?



enGene Therapeutics Inc has a total outstanding shares of 0

enGene Therapeutics Inc (ENGN) Financial

ENGN Stock Price Chart